Home / News / Publications

Publications

Precision Mapping of Retinal Disease: Identification of Differential Progression Trajectories via Imaging Phenomics

C. Anderson, L. Scott, I. Leung, et al., “ Precision Mapping of Retinal Disease: Identification of Differential Progression Trajectories via Imaging Phenomics,” iMetaMed 0 (2026): e70054.

Masquerading disease of macular telangiectasia type 2 – MacTel Project Report No 11

Laurenz Pauleikhoff, Peter Charbel Issa, Tjebo F.C. Heeren, Lea Scheppke, Daniel Pauleikhoff, Catherine Egan, Tunde Peto, Clemens Lange,Masquerading disease of macular telangiectasia type 2 – MacTel Project Report No 11, Ophthalmology Retina, 2026, ISSN 2468-6530

Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2

Goldberg RA, Manning DC, Yankey J, Clark WL, Bitar MI, Chew EY, Friedlander M, Khanani AM, Jaffe GJ, Lad EM, Aaberg TM Jr; MacTel Study Group. Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2. Ophthalmol Retina. 2026 Jul 20:S2468-6530(26)00351-9. doi:...

Long-term Progression of Ellipsoid Zone Loss and Associated Features on OCT in Macular Telangiectasia Type 2

Raming K, Goerdt L, Begemann E, Steffens N, Rodriguez Garcia JL, Egan C, Lange C, Tzaridis S, Friedlander M, Heeren T, Charbel Issa P, Holz FG, Pfau M, Pfau K. Long-term Progression of Ellipsoid Zone Loss and Associated Features on OCT in Macular Telangiectasia Type 2. Ophthalmology. 2026 Apr;133(4):522-531. doi:...

Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2

Singerman LJ, Hubschman JP, Friedlander M, Chew EY, Egan C, Bitar M, Aaberg TM Jr. Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2. Ophthalmol Sci. 2025 Nov 14;6(2):101009. doi: 10.1016/j.xops.2025.101009. PMID: 41725832; PMCID: PMC12919269.

Cell-based regenerative therapy for retinal diseases: challenges and emerging bioengineering strategies

Iwama Y, Masuda T, Maeyama A, Eade KT, Friedlander M, Nishida K, Mandai M. Cell-based regenerative therapy for retinal diseases: challenges and emerging bioengineering strategies. Regen Ther. 2025 Nov 14;30:1101-1112. doi: 10.1016/j.reth.2025.11.002. PMID: 41323371; PMCID: PMC12664435.

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2

Chew EY, Gillies M, Jaffe GJ, Gaudric A, Egan C, Constable I, Clemons T, Aaberg T, Manning DC, Hohman TC, Bird A, Friedlander M; MacTel CNTF NTMT-03 Research investigators. Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2. NEJM Evid. 2025 Aug;4(8):EVIDoa2400481. doi: 10.1056/EVIDoa2400481. Epub 2025 Jul 22. PMID:...

Enhanced Macular Telangiectasia Type 2 Detection: Leveraging Self-Supervised Learning and Ensemble Models

Gholami S, Scheppke L, Kshirsagar M, Wu Y, Dodhia R, Bonelli R, Leung I, Sallo FB, Muldrew A, Jamison C, Peto T, Ferres JL, Weeks WB, Friedlander M, Lee AY; Lowy Medical Research Institute. Enhanced Macular Telangiectasia Type 2 Detection: Leveraging Self-Supervised Learning and Ensemble Models. Ophthalmol Sci. 2025 Jan...

Developing a 10-Layer Retinal Segmentation for MacTel Using Semi-Supervised Learning

Verma A, Tzaridis S, Blazes M, Friedlander M, Lee AY, Wu Y. Developing a 10-Layer Retinal Segmentation for MacTel Using Semi-Supervised Learning. Transl Vis Sci Technol. 2024 Nov 4;13(11):2. doi: 10.1167/tvst.13.11.2. PMID: 39499591; PMCID: PMC11542501.

Serine and glycine physiology reversibly modulate retinal and peripheral nerve function

Lim EW, Fallon RJ, Bates C, Ideguchi Y, Nagasaki T, Handzlik MK, Joulia E, Bonelli R, Green CR, Ansell BRE, Kitano M, Polis I, Roberts AJ, Furuya S, Allikmets R, Wallace M, Friedlander M, Metallo CM, Gantner ML. Serine and glycine physiology reversibly modulate retinal and peripheral nerve function. Cell...

Older Publications